The Insider Selling: Jazz Pharmaceuticals PLC (JAZZ) COO Sells 4,000 Shares of Stock

The Insider Selling: Jazz Pharmaceuticals PLC (JAZZ) COO Sells 4,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) COO Russell J. Cox sold 4,000 shares of Jazz Pharmaceuticals PLC stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $128.75, for a total value of $515,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 3.26% during trading on Thursday, reaching $124.42. 754,688 shares of the company were exchanged. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $160.00. The company’s 50-day moving average is $109.08 and its 200 day moving average is $122.54. The firm has a market capitalization of $7.45 billion, a PE ratio of 21.76 and a beta of 1.30.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 EPS for the quarter, missing the Zacks’ consensus estimate of $2.61 by $0.04. The company had revenue of $374 million for the quarter, compared to analysts’ expectations of $389.34 million. Jazz Pharmaceuticals PLC had a return on equity of 30.50% and a net margin of 24.81%. The business’s revenue was up 9.8% compared to the same quarter last year. During the same period last year, the business posted $2.52 earnings per share. Equities research analysts expect that Jazz Pharmaceuticals PLC will post $9.96 EPS for the current fiscal year.

Several analysts recently issued reports on the company. Cantor Fitzgerald set a $187.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Wednesday. Leerink Swann reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday. SunTrust Banks Inc. reissued a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Thursday. Deutsche Bank AG reissued a “buy” rating and issued a $148.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Thursday. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and issued a $170.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Jazz Pharmaceuticals PLC currently has a consensus rating of “Buy” and a consensus price target of $178.25.

Institutional investors have recently modified their holdings of the company. Cadian Capital Management LP raised its position in shares of Jazz Pharmaceuticals PLC by 71.6% in the third quarter. Cadian Capital Management LP now owns 1,311,292 shares of the specialty pharmaceutical company’s stock worth $159,296,000 after buying an additional 547,056 shares during the period. BlackRock Fund Advisors raised its position in shares of Jazz Pharmaceuticals PLC by 4.8% in the third quarter. BlackRock Fund Advisors now owns 1,047,135 shares of the specialty pharmaceutical company’s stock worth $127,206,000 after buying an additional 47,834 shares during the period. Pioneer Investment Management Inc. raised its position in shares of Jazz Pharmaceuticals PLC by 36.4% in the third quarter. Pioneer Investment Management Inc. now owns 643,783 shares of the specialty pharmaceutical company’s stock worth $78,207,000 after buying an additional 171,694 shares during the period. Wells Fargo & Company MN raised its position in shares of Jazz Pharmaceuticals PLC by 17.2% in the third quarter. Wells Fargo & Company MN now owns 506,079 shares of the specialty pharmaceutical company’s stock worth $61,478,000 after buying an additional 74,342 shares during the period. Finally, Fiera Capital Corp bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter worth approximately $46,955,000. 89.21% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Related posts

Leave a Comment